Data Sheet (Cat.No.T27706)

TargetMol

K-111

Chemical Properties



CAS No. : 221564-97-2

Formula: C18H25Cl3O2

Molecular Weight: 379.75

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	K-111 (BM-170744) is an orally available peroxisome proliferator-activated receptor (PPAR)-alpha agonist and insulin enhancer for the study of obesity-type diabetes mellitus and the metabolic syndrome.
Targets(IC50)	PPAR
In vivo	K-111 treatment (chronic doses: 1, 3 and 10 mg/kg/d per 3 doses for 4 weeks) resulted in significant weight loss, improvement in hyperinsulinemia, insulin sensitivity, hypertriglyceridemia, and HDL cholesterol levels, and no significant effects on fasting glucose, 24-hour urinary excretion, systolic or diastolic blood pressure, plasma fibrinogen, total cholesterol, or chemical and hematological profile significant effect. [6]

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6333 mL	13.1666 mL	26.3331 mL
5 mM	0.5267 mL	2.6333 mL	5.2666 mL
10 mM	0.2633 mL	1.3167 mL	2.6333 mL
50 mM	0.0527 mL	0.2633 mL	0.5267 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Martins DE,et al. Ionic and biochemical characterization of bovine intervertebral disk. Connect Tissue Res. 2016 May;57(3):212-9.
Parsons SP, et al.Transient outward potassium current in ICC. Am J Physiol Gastrointest Liver Physiol. 2010 Mar;298 (3):G456-66.
Drew BG, et al.Drug evaluation: K-111, an insulin-sensitizing peroxisome proliferator-activated receptor alpha agonist. Curr Opin Investig Drugs. 2007 Apr;8(4):324-30. Review.
Murakami K, et al.Effect of PPARalpha activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes. Eur J Pharmacol. 2007 Apr 30;561(1-3):206-13.
Burger AM, et al. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 2005 Feb 15;65(4):1489-96.
Bodkin NL, et al. The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys. Horm Metab Res. 2003 Oct;35(10):617-24.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481